Daily Coverage San Francisco 2016


Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

  • Bookmark
  • Share this Video

Phase 1 Results for a Novel Anti-VEGF/Anti-ANG2 Antibody

by Pravin Dugel, MD

Pravin Dugel, MD, reviews the results of a phase 1 study evaluating RG7716, a novel anti-VEGF/anti-angiopoietin2 bispecific monoclonal antibody with potential to treat wet age-related macular degeneration and diabetic macular edema. Dr. Dugel reports on the results of the study and previews a pair of forthcoming phase 2 studies.

Comments (0)